CCL21 and non-small cell lung carcinoma: The safety and clinical activities of the intratumoral administration of autologous DC-CCL21 were evaluated in patients with pathologically confirmed and radiographically measurable NSCLC (Stage IIIB/IV) who had tumor accessible by CT-guided or bronchoscopic intervention, and were refractory to standard therapy [7].